AVROBIO to Participate in Four Upcoming Investor Conferences in September

Rhea-AI Summary

AVROBIO, a clinical-stage gene therapy company, announced its participation in four investor conferences scheduled between September 6-14, 2022. These include Citi's BioPharma Conference, Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, and Morgan Stanley's Global Healthcare Conference. AVROBIO aims to revolutionize treatment for genetic diseases through its proprietary plato® gene therapy platform, targeting conditions such as cystinosis and Gaucher disease. Presentations will be available on their website, and archived for 90 days.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming investor conferences:

Citi's 17^th Annual BioPharma Conference
Dates: Tuesday, Sept. 6, 2022 – Thursday, Sept. 8, 2022
Location: Four Seasons Hotel, Boston, Mass

2022 Wells Fargo Healthcare Conference
Dates: Wednesday, Sept. 7, 2022 – Friday, Sept. 9, 2022
Location: Encore Boston Harbor, Boston, Mass

H.C. Wainwright 24^th Annual Global Investment Conference
Dates: Monday, Sept. 12, 2022 – Wednesday Sept. 14, 2022
A pre-recorded presentation will be available on the investors section of avrobio.com starting on Monday, Sept. 12 at 7:00 a.m. ET

Morgan Stanley 20^th Annual Global Healthcare Conference
Fireside Chat Date: Tuesday, Sept. 13, 2022
Time: 1:30 p.m. ET
Location: Sheraton Hotel, New York, NY
A live webcast will be made available on the investors section of avrobio.com.

The webcast events will remain archived on the AVROBIO website for approximately 90 days.

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal to durably express the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for cystinosis and Gaucher disease type 1, as well as preclinical programs for Gaucher disease type 3, Hunter syndrome and Pompe disease. Our proprietary plato® gene therapy platform is designed to be scaled to support late-stage clinical development and commercialization globally. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com and follow us on Twitter and LinkedIn.

Forward-Looking Statement

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our current and prospective product candidates, the expected safety profile of our investigational gene therapies, results of preclinical studies, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, the timing of patient recruitment and enrollment activities, our plans and expectations with respect to interactions with regulatory agencies and the timing and likelihood of success thereof, the expected benefits and results of our implementation of the plato^® platform in our clinical trials and gene therapy programs and its potential impact on our manufacturing and commercialization activities, and statements regarding our financial and cash position and expected cash runway, including impact on anticipated milestones. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato^® platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, including sole source suppliers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Annual or Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005278/en/

Investor Contact:

Christopher F. Brinzey

Westwicke, an ICR Company

339-970-2843

chris.brinzey@westwicke.com



Media Contact:

Kit Rodophele

Ten Bridge Communications

617-999-9620

krodophele@tenbridgecommunications.com

Source: AVROBIO, Inc.

FAQ

What investor conferences is AVRO participating in September 2022?

AVROBIO is participating in Citi's BioPharma Conference, Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, and Morgan Stanley's Global Healthcare Conference from September 6-14, 2022.

What is AVROBIO's focus in gene therapy?

AVROBIO focuses on treating genetic diseases by introducing functional copies of affected genes into patients’ hematopoietic stem cells using their plato® gene therapy platform.

Where will the AVROBIO presentations be available?

Presentations by AVROBIO will be available on their website and archived for approximately 90 days after the conferences.

What conditions does AVROBIO target with its therapies?

AVROBIO targets genetic diseases including cystinosis and Gaucher disease type 1, along with preclinical programs for Gaucher disease type 3, Hunter syndrome, and Pompe disease.

What is the ticker symbol for AVROBIO?

The ticker symbol for AVROBIO is AVRO, and it is listed on NASDAQ.